Applied Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Mailing Address 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Phone 212-220-9226
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
-$105.62M
Net Income
$86.69M
Total Assets
$71.98M
Total Liabilities
$4.06M
Stockholders' Equity
$79.40M
Cash & Equivalents
$-1.42
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | January 2, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | December 31, 2025 | View on SEC |
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.